
    
      Phase 2, open label, multi-center, 2-period study to compare the pharmacodynamics of IV
      lansoprazole 30 mg to oral lansoprazole 30 mg in subjects with erosive esophagitis (grade
      >or= 2)diagnosed by endoscopy.
    
  